Viewing Study NCT06661720


Ignite Creation Date: 2025-12-25 @ 4:11 AM
Ignite Modification Date: 2025-12-26 @ 3:10 AM
Study NCT ID: NCT06661720
Status: RECRUITING
Last Update Posted: 2025-12-09
First Post: 2024-10-25
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Sponsor: Alliance for Clinical Trials in Oncology
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module